Key Insights

Highlights

Treatment Research

5 treatments under study, led by Abte2 1 Mg Neta 05 Mg

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05894135Phase 3Unknown

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Showing all 1 trials

Research Network

Common Treatments

  • Abte2 1 Mg Neta 05 Mg1
  • Bg2109 100mg1
  • Bg2109 100mg Placebo1
  • Bg2109 200mg1
  • Bg2109 200mg Placebo1

Active Sponsors

  • Bio Genuine (Shanghai) Biotech Co., Ltd.1

Top Investigators

  • Congjian Xu1

    Obstetrics & Gynecology Hospital of Fudan University

Related Conditions

  • Endometriosis1

Activity Timeline